United States:
USPTO Extends "Patents 4 Patients" Pilot; "Extended Missing Parts" Pilot Not Extended
03 January 2019
Oblon, McClelland, Maier & Neustadt, L.L.P
To print this article, all you need is to be registered or login on Mondaq.com.
The USPTO issued a release stating:
In response to the
continued interest of stakeholders around the world, the USPTO has
extended the Patents 4 Patients Cancer Immunotherapy Pilot
Program through June 30, 2020. All pilot parameters remain the
same as first implemented on June 29, 2016.
The Extended Missing Parts Pilot Program has not
been extended and will end January 2, 2019 as scheduled.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
